It has seen advances in new drug classes such as cholinesterase inhibitors.
According to Technavio, the global Alzheimer’s disease treatment market size is expected to expand by USD 5.41b from 2024 to 2028, with a compound annual growth rate expected to be 10.03% during the forecast period.
Technavio said in its analysis that the availability, research and development of novel biomarkers is driving market growth, with the emergence of regenerative therapies trending. However, the high cost of developing treatments poses a challenge.
As Alzheimer’s disease continues to be a major health concern, its treatment market is progressing with the introduction of drug classes such as cholinesterase inhibitors and beta-amyloid inhibitors. Biological therapies such as tau antibodies are also in the pipeline.
Technavio said life expectancy and memory impairment are driving high prescription rates.
Distribution channels including hospitals, pharmacies and e-commerce platforms are designed to improve access. At the same time, smartphones and the Internet have facilitated access to essential medicines through e-commerce.
Despite these advances, there are still no disease-modifying therapies for this disease. Technavio notes that researchers continue to work toward finding treatments, focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment.
